Qsartan tablet uses and side effects and Price

Qsartan (Losartan Potassium) 25mg & 50mg Tabiets

DESCRIPTION:

The active ingredient of Qsartan is Losartan Potassium. Losartan Potassium is an angiotensin receptor antagonist. yl)-1H-imidazole-5-yl)methanol. Its statement is C, H, CIKN, O.

COMPOSITION:

Qsartan (Losartan Potassium) is accessible for oral administration as:

Qsartan Tablet 25mg
Each film-coated tablet contains
Losartan Potassium USP...25mg Mfg. Specs.: USP

Qsartan Tablet 50mg
Each film-coated tablet contains
Losartan Potassium USP... Mfg. Specs.: USP .50mg

PHARMACOLOGY:

Angiotensin Il may be a potent vasoconstrictor, the vasoactive hormone of the renin-angiotensin system, and a significant component within the pathophysiology of hypertension. It also stimulates aldosterone secretion by the gland.

 Losartan Potassium and its active metabolites block the vasoconstricting and aldosterone secreting effects of angiotensin by selectively blocking the binding site of angiotonin. Both Losartan and its principal active metabolite have some way greater affinity (about 1000-folds) for the AT1 receptor than for the AT2 receptor.
The active metabolite is 10 to 40 times strenuous by weight than losartan and appears to be a reversible, noncompetitive inhibitor of the AT1 receptor.

 Losartan is an orally agent that undergoes substantial first-pass metabolism by cytochrome P450 enzymes. it's converted, in part, to a full of life acid metabolite that's responsible for most of the Hypertension receptor antagonism.

The terminal half-life of Losartan is about 2 hours and thus the metabolite is about 6-9 hours. Following oral administration, Losartan is well absorbed and undergoes substantial firstpass metabolism the systemic bioavailability of Losartan is approximately 33 %. About 14% of an orally administered dose of Losartan is converted to the active metabolites.
Mean peak concentrations of Losartan and its active metabolites. are reached. in 1hour and in 3-4 hours, respectively.

A meal slows the absorption of Losartan and reduces its Cmax but has only minor effects on Losartan AUC or on the AUC of the metabolites (about 10% decreased). Both Losartan and its active metabolites are highly bound to plasma proteins, primarily albumin, with plasma-free fractions of 1.3% and 0.2% respectively. the number of distribution of Losartan is about 34 liters and of the active metabolites is about 12 liters.

When Losartan is run orally, about 4% of the dose is excreted unchanged within the urine and about 6% is excreted in urine as active metabolites. Biliary excretion contributes to 60% of the elimination of Losartan and its metabolites.

Qsartan tablet INDICATIONS:

Hypertension: Qsartan is indicated for the treatment of hypertension. it should be used alone or along with other antihypertensive agents, including diuretics.
Hypertensive Patients with Left Ventricular Hypertrophy: Qsartan is indicated to chop back the possibility of stroke in patients with hypertension and left ventricular hypertrophy.
 Nephropathy in Type 2 Diabetic Patients: Qsartan is indicated for the treatment of diabetic nephropathy with elevated serum creatinine and proteinuria (urinary albumin to creatinine ratio 300 mg/g) in patients with Type 2 Diabetes and a history of hypertension.

WARNINGS:

Hypotension in volume-depleted Patients: In patients who are intravascularly volume-depicted (e.g. í those treàted wíth diuretics), symptomatic hypotension may occur after initiation of therapy wíth Losartan. These conditions should be corrected before administration of Losartan, or a lower starting dose should be used.

Impaired Hepatic Function:

A lower dose should be considered for patients with impaired liver function.

Impaired Renal Function:

As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function are reported in susceptible individuals treated with Losartan.

 Electrolyte Imbalance:

Electrolyte imbalances are common in patients with renal impairment with or without diabetes.

Potassium Supplements:

A patient receiving Losartan should be told to not use potassium supplements or salt substitutes containing potassium without consulting the prescribing physician. Fetal / Neonatal Morbidity & Mortality: Drugs that act directly on the renin - angiotensin system can cause fetal and neonatal morbidíty and death when administered to pregnant women's. When pregnancy is detected, Losartan should be discontinued as soon as possible.

Nursing Mothers:

due to the potential for adverse effects on the nursing infant, a call should be made whether to discontinue nursing or discontinue the drug, taking into consideration the importance of the drug to the mother.

Qsartan tablet DOSAGE & ADMINISTRATION:

Adult Hypertensive Patients: Qsartan is additionally administered with other antihypertensive agents, with or without food. Dosing must be individualized. the quality starting dose of Qsartan is 50mg once daily, with 25mg employed in patients with possible depletion of intravascular volume (e.g., patients treated with diuretics) and patients with a history of hepatic impairment.

Qsartan could also be administered once or twice daily with a whole daily dose ranging from 25mg to 100mg. No initial dosage adjustment is vital for elderly patients or for patients with renal impairment, including patients on dialysis.

 Pediatric Hypertensive Patients 2 6 Years of Age: the identical old recommended starting dose is 0.7mg/kg once daily (up to 50 mg total). Dosage should be adjusted to keep with sign response.

Hypertensive Patients with Left Ventricular Hypertrophy: the identical old starting dose is 50mg of Qsartan once daily. Hydrochlorothiazide 12.5mg daily should be added and/or the dose of Qsartan should be increased to 50mg twice daily followed by an increase in hydrochlorothiazide to 25mg once daily supported sign response.

 Nephropathy in Type 2 Diabetic Patients: the quality starting dose is 50mg once daily. The dose should be increased to 100mg once daily supported pressure response.

Qsartan could even be administered with insulin and other commonly used hypoglycemic agents (e.g.; sulfonylureas, glitazones, and glucosidase inhibitors).

SPECIAL INSTRUCTIONS TO THE PHYSICIAN: 

Overdosage: Hypotension and tachycardia; bradycardia could occur from overdosage due to parasympathetic (vagal) stimulation. íf symptomstic hypotension occurs supportive treatment should be instituted. Neither Losartan nor its active metabolites is also removed by hemodialysis.